Pharma major Lupin on August 29 said it has launched a generic cancer treatment drug, Doxorubicin Hydrochloride Liposome injection, in single-dose vials, in the US market.
The Mumbai-based drug maker introduced the product after its alliance partner, ForDoz Pharma Corporation, USA (ForDoz) received approval from the USFDA, Lupin said in a statement.
The company's product is a generic version of Baxter Healthcare Corporation's Doxil, which is indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s Sarcoma, and multiple myeloma.
ALSO READ: Lupin stock soars to 52-week high on strong all-round Q1 show
As per the Iqvia MATdata, Doxorubicin Hydrochloride Liposome injection had an estimated annual sales of $40.9 million in the US.
Lupin shares on Thursday ended 0.21 percent at Rs 2,195.20 apiece on the BSE.
(With PTI inputs)
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
